Recon: HHS ending use of Anthropic’s Claude AI; FDA gives breakthrough designation to AI chatbot for patients undergoing surgery

• HHS starts phasing out Anthropic’s Claude (STAT)
• CMS' Chris Klomp on what it will take for AI to succeed in healthcare (Endpoints)
• ICER calls on CMS to lower price of Takeda blockbuster Entyvio to Stelara's level (Endpoints)
• Drugmakers Pressure Trump to Withdraw Foreign Pricing Frameworks (Bloomberg Law)
• Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute (Reuters)
• Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval (Reuters)
• Exclusive: US postpones third consecutive meeting of preventive health panel (Reuters)

• Amid unfolding Middle East war, pharma giants keep close eye on employee safety, supply chains (Fierce Pharma)
• MAHA goes global: Inside the rise of the Make Europe Healthy Again movement (STAT)
• Aspen Pharmacare expects Canada entry with Ozempic generic by third quarter (Reuters)
• African drugmaker Aspen reports 21% earnings decline due to one-off costs (Reuters)
• Boston Scientific gets Farapulse label expansion in Europe (MedTech Dive)

• FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says (STAT)
• FDA grants ‘breakthrough’ status to generative AI chatbot for surgical patients (STAT)
• 6 key dilemmas as human embryo models get ever closer to the real thing (STAT)
• Geopolitics Now Play Key Role in Boardrooms, Fresenius CEO Says (Bloomberg)
• Theravance ends R&D, lays off half of workforce after repeated Phase 3 fails (Endpoints)
• Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work (Endpoints)
• Hims’ pharmacy partner will reintroduce GLP-1 pill pulled from market (Endpoints)
• Esperion to buy Corstasis and its nasal spray for edema for $75M upfront (Endpoints)
• Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports (Reuters)

• Diagnostics startup Droplet Biosciences partners with Nvidia to speed cancer test results (Reuters)
• RadNet to acquire radiology AI company Gleamer (MedTech Dive)
• Fresenius Kabi recalls Ivenix infusion pumps over software problem (MedTech Dive)
• Stakeholders Ask CMS For Additional TAVR Indications (MedTech Insight)

• Mondelēz CEO says M&A is harder as acquisition targets become ‘too expensive’ (Food Dive)
• State officials still finding recalled ByHeart infant formula on store shelves (Food Safety News)

• Federal Medicaid audit finds massive overpayment for autism therapy in Colorado (STAT)
• Cigna Elevates COO Evanko to Lead Major Business Model Pivot (Bloomberg)
• CMS halts enrollment in Elevance’s Medicare Advantage plans, citing years of misconduct (STAT)
• CDC acting director Bhattacharya urges use of measles vaccine (Reuters)
• Decentralized Trials Are On ‘Classic Path Of Normalization’ While ‘Solving Real Problems’ (Pink Sheet)